SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J Clin. 2001; 51: 1536.
  • 2
    Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology. 2001; 60: 818.
  • 3
    Rothenberg ML. New developments in chemotherapy for patients with advanced pancreatic cancer. Oncology. 1996; 10(9 Suppl ): 1822.
  • 4
    Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′2′ difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994; 12: 2934.
  • 5
    Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 24032413.
  • 6
    Taylor EC, Kuhnt D, Shih C, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem. 1992; 35: 44504454.
  • 7
    Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol. 1999; 26(2 Suppl 6 ): 4247.
  • 8
    Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997; 57: 11161123.
  • 9
    Schultz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res. 1999; 19: 437443.
  • 10
    Britten CD, Izbicka E, Hilsenbeck S, et al. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol. 1999; 44: 105110.
  • 11
    McDonald AC, Vasey PA, Adams L, et al. A Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res. 1998; 4: 605610.
  • 12
    Rinaldi DA, Burris HA, Dorr FA, et al. Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol. 1995; 13: 28422850.
  • 13
    Rinaldi DA, Kuhn JG, Burris HA, et al. A Phase I evaluation of multitargeted antifolate (MTA, LY231514) administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999; 44: 372380.
  • 14
    Miller KD, Picus J, Blanke C, et al. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol. 2000; 11: 101103.
  • 15
    Teicher BA, Chen V, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res. 2000; 6: 10161023.
  • 16
    Adjei AA, Erlichman C, Thornton D, et al. Synergistic cytotoxicity of MTA (LY231514) and gemcitabine in vitro and in vivo. 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Ann Oncol. 1998; 9: 168.
  • 17
    Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 1999; 59: 36713676.
  • 18
    Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol. 2000; 18: 17481757.
  • 19
    Worzalla JF, Shih C, Schultz RM. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res. 1998; 18: 32353239.
  • 20
    Niyikiza C, Walling J, Thornton D, Seitz D, Allen R. LY231514 (MTA): relationship of vitamin metabolite profile to toxicity [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 558a.